Author:
Golla Vijaya Madhyanapu,Kushwah Bhoopendra Singh,Dhiman Vivek,Velip Laximan,Samanthula Gananadhamu
Subject
Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry
Reference25 articles.
1. F.H. Tan, T.L. Putoczki, S.S. Stylli, R.B. Luwor, Ponatinib: A novel multi-tyrosine kinase inhibitor against human malignancies. Onco Targets and Ther., 12, 635–645.
2. BCR-ABL Inhibitors as Sensitizing Agents for Cancer Chemotherapy;Cui,2019
3. Ponatinib in refractory philadelphia chromosome–positive leukemias;Cortes;N. Engl. J. Med.,2012
4. Ponatinib: a drug review;Jain;Cancer Res. Stat. Treat.,2019
5. Spectrum of BCR-ABL mutations and treatment outcomes in ethiopian imatinib-resistant patients with chronic myeloid leukemia;Tadesse;JCO Glob. Oncol.,2021
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Nitrosamine contamination of pharmaceuticals: Cases in Japan, formation mechanisms, detection methods, regulatory perspectives, and insights;Journal of Pharmaceutical and Biomedical Analysis Open;2024-12
2. Analysis of omarigliptin forced degradation products by ultra‐fast liquid chromatography, mass spectrometry, and in vitro toxicity assay;Biomedical Chromatography;2024-05-29
3. <i>In Silico</i> Prediction of <i>N</i>-Nitrosamine Formation Pathways of Pharmaceutical Products;Chemical and Pharmaceutical Bulletin;2024-02-01
4. QbD-driven RP-HPLC method for novel chemo-herbal combination, in-silico, force degradation studies, and characterization of dual drug-loaded polymeric and lipidic nanocarriers;Future Journal of Pharmaceutical Sciences;2023-11-29
5. In Silico Tools to Thaw the Complexity of the Data: Revolutionizing Drug Research
in Drug Metabolism, Pharmacokinetics and Toxicity Prediction;Current Drug Metabolism;2023-11